Understanding Heart Problems from Chemotherapy in Children with Relapsed Leukemia
Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications
This project aims to better understand how chemotherapy for relapsed acute myeloid leukemia (AML) affects the hearts of children and adolescents.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11129826 on NIH RePORTER |
What this research studies
Children and adolescents with acute myeloid leukemia (AML) who experience a relapse face intensive chemotherapy, which can unfortunately lead to heart problems. We want to learn more about when these heart issues start, how they progress, and if children can recover from them. By looking at existing information from clinical trials and patient experiences, we hope to fill in the gaps in our current knowledge. This will help us understand the specific risks associated with different treatments for relapsed AML.
Who could benefit from this research
Good fit: This research focuses on children and adolescents, aged 0-11 years, who have experienced a relapse of acute myeloid leukemia and received intensive chemotherapy.
Not a fit: Patients who have not been diagnosed with acute myeloid leukemia or who have not undergone chemotherapy for relapsed disease would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to better ways to monitor and protect the hearts of children undergoing chemotherapy for relapsed AML, potentially improving their long-term health.
How similar studies have performed: While the overall prognosis for pediatric AML has improved, there is a current lack of comprehensive data specifically on cardiotoxicity risks during and after treatment for relapsed disease.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Getz, Kelly Diringer — University of Pennsylvania
- Study coordinator: Getz, Kelly Diringer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.